Private Wealth Partners LLC lessened its position in shares of Becton Dickinson and Co (NYSE:BDX) by 11.8% during the 2nd quarter, HoldingsChannel.com reports. The institutional investor owned 1,500 shares of the medical instruments supplier’s stock after selling 200 shares during the period. Private Wealth Partners LLC’s holdings in Becton Dickinson and were worth $359,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the stock. BlackRock Inc. grew its position in Becton Dickinson and by 0.7% during the first quarter. BlackRock Inc. now owns 18,936,564 shares of the medical instruments supplier’s stock valued at $4,103,552,000 after buying an additional 125,262 shares during the period. FMR LLC lifted its holdings in Becton Dickinson and by 13.7% during the second quarter. FMR LLC now owns 16,987,638 shares of the medical instruments supplier’s stock valued at $4,069,559,000 after purchasing an additional 2,049,874 shares in the last quarter. Franklin Resources Inc. lifted its holdings in Becton Dickinson and by 1.5% during the first quarter. Franklin Resources Inc. now owns 3,744,936 shares of the medical instruments supplier’s stock valued at $811,527,000 after purchasing an additional 55,004 shares in the last quarter. Putnam Investments LLC lifted its holdings in Becton Dickinson and by 0.5% during the second quarter. Putnam Investments LLC now owns 3,513,485 shares of the medical instruments supplier’s stock valued at $841,690,000 after purchasing an additional 18,859 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in Becton Dickinson and by 8.1% during the first quarter. Northern Trust Corp now owns 3,319,529 shares of the medical instruments supplier’s stock valued at $719,341,000 after purchasing an additional 247,339 shares in the last quarter. Institutional investors own 92.47% of the company’s stock.

NYSE:BDX opened at $257.23 on Tuesday. The company has a current ratio of 1.23, a quick ratio of 0.81 and a debt-to-equity ratio of 0.95. The stock has a market capitalization of $69.74 billion, a PE ratio of 27.13, a price-to-earnings-growth ratio of 1.78 and a beta of 1.11. Becton Dickinson and Co has a twelve month low of $191.53 and a twelve month high of $263.37.

Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Thursday, August 2nd. The medical instruments supplier reported $2.91 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.86 by $0.05. The firm had revenue of $4.28 billion for the quarter, compared to the consensus estimate of $4.25 billion. Becton Dickinson and had a net margin of 4.73% and a return on equity of 14.16%. The company’s revenue for the quarter was up 41.0% on a year-over-year basis. During the same period last year, the firm posted $2.46 earnings per share. research analysts anticipate that Becton Dickinson and Co will post 11.01 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 28th. Stockholders of record on Friday, September 7th will be paid a $0.75 dividend. This represents a $3.00 annualized dividend and a dividend yield of 1.17%. The ex-dividend date of this dividend is Thursday, September 6th. Becton Dickinson and’s dividend payout ratio is currently 31.65%.

Several equities analysts have issued reports on BDX shares. ValuEngine downgraded shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Tuesday, May 29th. JPMorgan Chase & Co. raised shares of Becton Dickinson and from a “neutral” rating to an “overweight” rating and set a $175.00 price objective on the stock in a report on Thursday, June 21st. KeyCorp reaffirmed a “buy” rating and set a $264.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Royal Bank of Canada reaffirmed a “hold” rating and set a $248.00 price objective on shares of Becton Dickinson and in a report on Friday, August 3rd. Finally, Citigroup increased their price objective on shares of Becton Dickinson and from $274.00 to $283.00 and gave the company a “buy” rating in a report on Wednesday, August 8th. Four research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $251.64.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.

Featured Story: Tariff

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.